{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T14:33:12Z","timestamp":1775658792103,"version":"3.50.1"},"reference-count":20,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,25]],"date-time":"2019-11-25T00:00:00Z","timestamp":1574640000000},"content-version":"vor","delay-in-days":3191,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004337","name":"F. Hoffmann-La Roche Ltd","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2011,3]]},"DOI":"10.1093\/annonc\/mdq430","type":"journal-article","created":{"date-parts":[[2010,9,7]],"date-time":"2010-09-07T00:12:59Z","timestamp":1283818379000},"page":"595-602","source":"Crossref","is-referenced-by-count":77,"title":["First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2251 patients"],"prefix":"10.1016","volume":"22","author":[{"given":"I.E.","family":"Smith","sequence":"first","affiliation":[]},{"given":"J.-Y.","family":"Pierga","sequence":"additional","affiliation":[]},{"given":"L.","family":"Biganzoli","sequence":"additional","affiliation":[]},{"given":"H.","family":"Cort\u00e9s-Funes","sequence":"additional","affiliation":[]},{"given":"C.","family":"Thomssen","sequence":"additional","affiliation":[]},{"given":"X.","family":"Pivot","sequence":"additional","affiliation":[]},{"given":"A.","family":"Fabi","sequence":"additional","affiliation":[]},{"given":"B.","family":"Xu","sequence":"additional","affiliation":[]},{"given":"D.","family":"Stroyakovskiy","sequence":"additional","affiliation":[]},{"given":"F.A.","family":"Franke","sequence":"additional","affiliation":[]},{"given":"B.","family":"Kaufman","sequence":"additional","affiliation":[]},{"given":"P.","family":"Mainwaring","sequence":"additional","affiliation":[]},{"given":"T.","family":"Pienkowski","sequence":"additional","affiliation":[]},{"given":"B.","family":"De Valk","sequence":"additional","affiliation":[]},{"given":"A.","family":"Kwong","sequence":"additional","affiliation":[]},{"given":"J.L.","family":"Gonz\u00e1lez-Trujillo","sequence":"additional","affiliation":[]},{"given":"I.","family":"Koza","sequence":"additional","affiliation":[]},{"given":"K.","family":"Petrakova","sequence":"additional","affiliation":[]},{"given":"D.","family":"Pereira","sequence":"additional","affiliation":[]},{"given":"K.I.","family":"Pritchard","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdq430_bb0010","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1002\/biof.46","article-title":"The function of vascular endothelial growth factor","volume":"35","author":"Nieves","year":"2009","journal-title":"Biofactors"},{"key":"10.1093\/annonc\/mdq430_bb0015","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/nm0603-669","article-title":"The biology of VEGF and its receptors","volume":"9","author":"Ferrara","year":"2003","journal-title":"Nat Med"},{"key":"10.1093\/annonc\/mdq430_bb0020","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1056\/NEJMoa072113","article-title":"Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer","volume":"357","author":"Miller","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdq430_bb0025","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1200\/JCO.2008.21.6457","article-title":"Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer","volume":"28","author":"Miles","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq430_bb0030","doi-asserted-by":"crossref","first-page":"4966","DOI":"10.1200\/JCO.2008.21.6630","article-title":"Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer","volume":"27","author":"Gray","year":"2009","journal-title":"J Clin Oncol"},{"issue":"Suppl","key":"10.1093\/annonc\/mdq430_bb0035","first-page":"15s","article-title":"RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC)","volume":"27","author":"Robert","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq430_bb0040","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1200\/JCO.2005.05.098","article-title":"Randomized, phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer","volume":"23","author":"Miller","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq430_bb0045","year":"2006","journal-title":"National Cancer Institute\u2014Common Terminology Criteria for Adverse Events v3.0 (CTCAE)"},{"key":"10.1093\/annonc\/mdq430_bb0050","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdq052","article-title":"Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapy","author":"Bidard","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdq430_bb0055","doi-asserted-by":"crossref","unstructured":"Etienne-Grimaldi M-C, Formento P, Degeorges A, et al. Impact of germinal vascular endothelial growth factor-A (VEGF-A) gene polymorphisms on pharmacodynamics of bevacizumab in metastatic breast cancer patients treated as first-line therapy: a French companion study of the open label international multicenter MO19391 trial. Proceedings of the American Association for Cancer Research Annual Meeting 2010, April 17\u201321, Washington, DC, USA (Abstr 2751).","DOI":"10.1158\/1538-7445.AM10-2751"},{"key":"10.1093\/annonc\/mdq430_bb0060","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S1470-2045(09)70112-3","article-title":"Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis","volume":"10","author":"Hapani","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdq430_bb0065","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/j.ijrobp.2005.12.004","article-title":"Increased risk of ischemic bowel complications during treatment with bevacizumab after pelvic irradiation: report of three cases","volume":"64","author":"Lordick","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1093\/annonc\/mdq430_bb0070","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1093\/annonc\/mdp233","article-title":"Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study","volume":"20","author":"Van Cutsem","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdq430_bb0075","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1634\/theoncologist.2009-0071","article-title":"Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study","volume":"14","author":"Kozloff","year":"2009","journal-title":"Oncologist"},{"key":"10.1093\/annonc\/mdq430_bb0080","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S1470-2045(10)70151-0","article-title":"Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study","volume":"11","author":"Crin\u00f2","year":"2010","journal-title":"Lancet Oncol"},{"issue":"Suppl","key":"10.1093\/annonc\/mdq430_bb0085","first-page":"50s","article-title":"Independent review of E2100 progression-free survival (PFS) with the addition of bevacizumab (B) to paclitaxel (P) as initial chemotherapy for metastatic breast cancer (MBC)","volume":"26","author":"Klencke","year":"2008","journal-title":"J Clin Oncol"},{"issue":"Suppl","key":"10.1093\/annonc\/mdq430_bb0090","first-page":"512s","article-title":"Comparison of subgroup analyses of PFS from three phase III studies of bevacizumab in combination with chemotherapy in patients with HER2-negative metastatic breast cancer","volume":"69","author":"O'Shaughnessy","year":"2009","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdq430_bb0095","doi-asserted-by":"crossref","first-page":"3950","DOI":"10.1200\/JCO.2007.11.9362","article-title":"Gemcitabine plus paclitaxel versus paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment","volume":"26","author":"Albain","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq430_bb0100","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1200\/JCO.2002.09.002","article-title":"Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results","volume":"20","author":"O'Shaughnessy","year":"2002","journal-title":"J Clin Oncol"},{"issue":"15s","key":"10.1093\/annonc\/mdq430_bb0105","article-title":"Bevacizumab (Bev) combined with either capecitabine (X) or weekly paclitaxel (Pac) as first-line chemotherapy (CT) for HER2-negative, locally recurrent or metastatic breast cancer (LR\/MBC): preliminary safety data from the CECOG phase III TURANDOT trial","volume":"28","author":"Lang","year":"2010","journal-title":"J Clin Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419386193?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419386193?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/22\/3\/595\/720228\/mdq430.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T09:27:06Z","timestamp":1624699626000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419386193"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,3]]}},"alternative-id":["S0923753419386193"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdq430","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2011,3]]}}}